LBA92Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
Burgers, S A, de Gooijer, C, Cornelissen, R, Aerts, J G, Biesma, B, Heemst, R V, Youssef-El Soud, M, Groen, H J M, Staal-van den Brekel, A J, Bootsma, G, Schijen, J H E M, Baas, P, Giovannetti, E, de Vries, J F, Hogenboom, F A, de Wit, D C M, Mahn- Schaefers, M C W, Lalezari, F, van de Noort, V, Stigt, J
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
LBA92 - Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
Burgers, S.A., de Gooijer, C., Cornelissen, R., Aerts, J.G., Biesma, B., Heemst, R.V., Youssef-El Soud, M., Groen, H.J.M., Staal-van den Brekel, A.J., Bootsma, G., Schijen, J H E M, Baas, P., Giovannetti, E., de Vries, J.F., Hogenboom, F.A., de Wit, D.C.M., Mahn- Schaefers, M.C.W., Lalezari, F., van de Noort, V., Stigt, J.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
Burgers, S.A., de Gooijer, C., Cornelissen, R., Aerts, J.G., Biesma, B., Heemst, R.V., Youssef-El Soud, M., Groen, H.J.M., Staal-van den Brekel, A.J., Bootsma, G., Schijen, J H E M, Baas, P., Giovannetti, E., de Vries, J.F., Hogenboom, F.A., de Wit, D.C.M., Mahn- Schaefers, M.C.W., Lalezari, F., van de Noort, V., Stigt, J.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article